U.S. Communications Stock News

Comstock Resources (CRK) turned profitable over the past five years, boasting average annual earnings growth of 8.6% and posting net profit margins finally in positive territory. Wall Street is sizing up this momentum, with forecasts calling for a massive 74.6% annual earnings growth, which easily outpaces the US market’s expected 16%. Revenue, meanwhile, is projected to rise at 9.8% per year, just a touch behind the US average of 10.5%. See our full analysis for Comstock Resources. Next, we...

SOPHiA GENETICS (NasdaqGS:SOPH) is forecast to post annual revenue growth of 17.91%, surpassing the broader US market's expected 10.5% rate. The company has not yet achieved profitability and losses have actually grown at 4% per year for the past five years, with its net profit margin still in negative territory. For investors, the critical narrative is clear: the top-line growth potential stands out, but persistent losses and questions around the path to profitability remain a defining...

Greenlight Capital Re (GLRE) remains unprofitable, but the company has narrowed its losses over the last five years at an annual rate of 25.2%. Despite the ongoing challenges to net profit margin, the stock is drawing investor attention thanks to a low Price-To-Sales Ratio of 0.6x versus a peer average of 4.9x and a trading price of $11.95, well below an estimated fair value of $20.06. With risk sentiment steady and no major negative headlines, the current results put the spotlight on...

Xometry (XMTR) remains unprofitable, with net losses rising at an annual rate of 2.3% over the past five years and no meaningful progress on profit margins. Despite persistent losses, revenue is forecast to increase by 14.8% per year, which would outpace the broader US market's 10.5% growth. Earnings are projected to jump 99% annually, with profitability expected within three years. Investors attracted to Xometry's rapid top-line growth and the promise of a turnaround must weigh this optimism...

Bowhead Specialty Holdings (BOW) posted an impressive set of headline numbers, with earnings forecast to grow at 23.5% per year, well above the US market average of 16%, and revenue projected to rise 19.3% annually compared to the broader market’s 10.5%. Net profit margin improved to 10.1% from last year’s 7.6%, signaling a clear strengthening in profitability. With earnings quality described as high and expectations set for robust growth, investors are likely to focus on the company's...

Bioventus (BVS) recently swung to profitability in the past year, despite an average earnings decline of 16.6% per year over the last five years. The bottom line was affected by a non-recurring loss of $17.3 million for the twelve months ending September 27, 2025. Although revenue is forecast to grow at 6.1% annually, this pace trails the broader US market's 10.5% average. Trading at $7.55, the stock sits well below its estimated fair value of $17.96 and also below analyst targets. Its high...

Driven Brands Holdings (DRVN) remains unprofitable, with losses accelerating at an average rate of 48.1% per year over the past five years. However, analysts expect earnings to grow by 56.02% annually, projecting the company will achieve profitability within the next three years. This outlook stands above market averages. Revenue is forecast to grow 4% per year, which is slower than the 10.5% US market average, but the company’s valuation continues to attract attention as shares trade well...

ADT (ADT) reported a net profit margin of 12.8%, up from 11% the previous year, highlighting a notable improvement in profitability. While the company posted 23.3% earnings growth for the most recent year, this is below its impressive five-year annual average of 67.7%. With shares trading at $8.08, well under the estimated fair value of $19.86, investors are weighing the appeal of rising margins and an attractive valuation against concerns over ADT’s less favorable financial position. See our...

Dave (DAVE) posted a net profit margin of 29.8%, jumping from 12.9% last year, as revenue is projected to grow at 15% annually, outpacing the US market’s 10.5% average. Over the past year, earnings soared 255.6%, far exceeding the company’s already impressive five-year average of 43.4% annual growth. With high-quality earnings, improved margins, and momentum on both the revenue and profit fronts, investors are likely to zero in on these operational gains as a sign of sustained business...

Paymentus Holdings (PAY) posted net profit margins of 5.3%, a slight uptick from last year's 5.2%. Over the past five years, earnings have surged at an impressive 57.4% annual rate, but the latest annual earnings growth of 47% fell short of this pace. Looking ahead, analysts expect earnings to grow 28.1% per year and revenue to expand 19.6% annually. Both figures outpace the broader US market, yet shares trade well above DCF-based estimates with a price-to-earnings ratio of 76.1x. See our...

Telesat (TSAT) remains unprofitable, with losses accelerating at an average rate of 54.1% a year over the past five years. Despite the red ink, the company’s revenue is forecast to grow 23.6% annually, outpacing the US market’s 10.5% projection. While top-line expansion is impressive, TSAT’s net profit margin has yet to improve and the company is expected to stay unprofitable for at least the next three years, putting sustained pressure on investor confidence. See our full analysis for...

AdaptHealth (AHCO) recently turned profitable, with its net profit margin shifting notably over the past year. Despite a -16.2% average annual earnings growth over the last five years, forecasts now call for earnings to grow at 23.1% per year, outpacing the broader US market’s 16%. While revenue is expected to rise 7.3% per year in the coming period, which trails the US average, high earnings quality and significant near-term profit growth are clear upside drivers for investors who see value...

Global Payments (GPN) posted a net profit margin of 16.2%, up from 13.8% a year ago, and earnings have grown at an impressive 24% per year over the past five years, with a standout 34.4% gain in the last year alone. While revenue and projected annual earnings are expected to grow at a slower pace than the broader US market, the company’s high earnings quality and forward profit growth continue to draw attention as shares trade below estimates of fair value and at a Price-To-Earnings ratio of...

Medifast (MED) is facing a tough outlook, with both revenue and earnings forecast to decline sharply over the next three years. Revenue is expected to decrease by 12.5% per year, and earnings are projected to fall by 146.7% annually, following a recent year in which net profit margins slipped to just 0.06%, down from 1.1% last year. The company also recorded a one-off loss of $12.5 million in the last twelve months, adding extra pressure to already weakening earnings. In fact, average annual...

Spire Global (SPIR) recently became profitable, with its net profit margin turning positive over the past year. Despite crossing into the black, earnings are forecast to decline sharply at an annual rate of 70% over the next three years, even as revenue is projected to grow just 2.5% per year, lagging far behind the US market average of 10.5%. For investors, this means the company is coming off a milestone of positive earnings, but expectations remain muted due to forecasts for falling...

Core Molding Technologies (CMT) is aiming for a massive 46.5% annual EPS growth rate over the next three years, which easily outpaces the US market average of 16%. This outlook comes as the company posts a forecasted 6.4% revenue growth per year, lagging the US market’s 10.5% average, and a net profit margin of 3.1%, down from 4.9% a year ago. After growing earnings at 20.7% per year over the last five years, CMT enters this period with a high-quality earnings track record but faces margin...

Taysha Gene Therapies (TSHA) remains unprofitable, but its revenue is forecast to grow rapidly by 70.5% per year, far outpacing the broader US market's expected 10.5% annual growth. Over the past five years, the company has managed to cut its losses at a 7.5% annual rate, even as it is projected to stay in the red for at least the next three years. With shares recently trading at $4.27, below an estimated fair value of $20.71, investors are weighing the promise of significant top-line growth...

Portillo’s (PTLO) is forecast to grow revenue at 8.5% per year, which trails the broader US market’s pace of 10.5%. Despite this, the company’s earnings are expected to climb 16.9% per year, a notch above the market’s 16% average, while net profit margins edged down to 3.4% from last year’s 3.6%. Investors are watching this mix of slower sales growth but faster earnings momentum, especially as the company maintains modest profitability and a valuation that sits between direct peers and the...

Leidos Holdings (LDOS) posted 16.9% earnings growth for the past year, outpacing its five-year average of 13.7% per year. Net profit margin also improved to 8.1% from last year’s 7.4%, while management continues to deliver high-quality results. Looking ahead, consensus expects earnings to increase by 3.5% per year and revenue by 2.7%, both trailing the broader U.S. market averages. See our full analysis for Leidos Holdings. Next, we will see how these headline numbers compare to the current...

Castle Biosciences (CSTL) continues to operate at a loss, with recent filings confirming the company has yet to achieve net profit margin improvement over the past year and is still generating negative earnings. Despite reducing its annual losses at a rate of 9.6% per year over the last five years, it remains on a slower growth path. Forecasted revenue is expected to rise 6.5% per year, lagging behind the broader US market’s 10.5% annual growth rate. With profitability still out of reach in...

LGI Homes (LGIH) reported a 20.4% annual decline in earnings over the past five years, with current net profit margins at 5.9% compared to 8.8% previously. However, revenue is projected to grow at 17.4% per year, while EPS is expected to jump by 27.4% annually for the next three years, outpacing the broader US market’s 16% outlook. With margins under recent pressure but robust growth prospects ahead, investors will be weighing risks from declining profitability against strong forward-looking...

Rhythm Pharmaceuticals (RYTM) reported widening losses, with net losses having grown at a rate of 18.8% per year over the past five years. Despite being unprofitable, the company commands a Price-To-Sales Ratio of 40x, outpacing both the US Biotechs industry average of 10.8x and the peer average of 17.9x, positioning its stock as highly valued on these multiples. On the growth front, forecasts point to revenue expanding at 45.8% per year and earnings projected to grow 70.56% per year, with...

PRA Group (PRAA) is currently unprofitable, with losses having grown at an average annual rate of 48.8% over the last five years. While revenue is projected to grow at 6.6% per year, this is slower than the broader US market’s pace of 10.5% per year. The company is expected to remain unprofitable for at least the next three years. Margins have seen no improvement over the past year, signaling that profitability remains a persistent challenge for investors considering this stock. See our full...

Ormat Technologies (ORA) posted net profit margins of 14.1%, up from last year’s 13.3%, and delivered 16.7% average annual earnings growth over the past five years. However, the latest year’s earnings growth was 12.4%, trailing both the company’s own historical average and the projected pace of 8.1% earnings and 8.6% revenue growth going forward. Both figures are below the US market’s forecasted profit and revenue growth rates of 16% and 10.5%. These results come as the stock trades at a...